An extremely different dysmetabolic profile between the two available nonnucleoside reverse transcriptase inhibitors: efavirenz and nevirapine.
Manfredi
Roberto
R
Calza
Leonardo
L
Chiodo
Francesco
F
D000480:Alkynes; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects; D048588:Benzoxazines; D001786:Blood Glucose / Q000378:metabolism; D003430:Cross-Sectional Studies; D003521:Cyclopropanes; D015658:HIV Infections / Q000188:drug therapy* / Q000378:metabolism*; D006801:Humans; D008055:Lipids / Q000097:blood; D019829:Nevirapine / Q000009:adverse effects* / Q000627:therapeutic use; D010078:Oxazines / Q000009:adverse effects* / Q000627:therapeutic use; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects*
D000480:Alkynes; D048588:Benzoxazines; D001786:Blood Glucose; D003521:Cyclopropanes; D008055:Lipids; D010078:Oxazines; D018894:Reverse Transcriptase Inhibitors; D019829:Nevirapine; C098320:efavirenz